KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • Findings from the National Health and Wellness Survey (NHWS) show that patients diagnosed with IBS are more likely to suffer from headaches and migraines. Recent research suggests that there may be a link between these conditions.
  • It’s just not cricket

    by Mark Sales  |  Feb 26, 2016
    We have played at the edge of patient (and consumers who are at risk of becoming patients) data for far too long.
  • Opdivo (nivolumab, Bristol-Myers Squibb) is approved for the treatment of patients with squamous cell non-small cell lung cancer (NSCLC) who have relapsed on platinum-based chemotherapy. Based on the clinical trial that served as the basis for approval, Opdivo did not stratify response rates based on PD-L1 levels, and the approved label does not have a biomarker requirement.
  • Is There a Breaking Point for Immunotherapy Costs?

    by Debbie Warner  |  Jul 1, 2015
    Value was an overarching theme at ASCO 2015 and has been a topic of ongoing focus, as have been the burgeoning pipeline of immunotherapy agents, with the recently launched PD-1 inhibitors, Opdivo® (nivolumab, Bristol Myers Squibb) and Keytruda® (pembrolizumab, Merck), being the highlights of ASCO 2015. Presenter Leonard Saltz, M.D. of Memorial Sloan Kettering praised the clinical value of an Opdivo + Keytruda combination as being “truly, truly remarkable,” but he added that with the combination costing nearly $300,000 (if continued for 11 months) “these drugs cost too much –unsustainable.” While Dr. Saltz is an unabashed critic of cancer drug prices, $300,000 would give most people pause.
  • Like their Western counterparts, doctors in Korea have to now manage newly empowered patients who come to them armed with information and data gathered online. However, unlike their Western counterparts, Korean doctors have a history of being very active online.
More than one Google Analytics scripts are registered. Please verify your pages and templates.